SCHEDULE 13G: Madison Avenue Entities Disclose 8% Passive Stake in Sage Therapeutics

A group of investment entities associated with Madison Avenue, including Madison Avenue International LP and Eli Samaha, have disclosed a passive 8% beneficial ownership stake in Sage Therapeutics, Inc.

Summary

• A group of Reporting Persons, including Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha, have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 4,920,763 shares of Sage Therapeutics, Inc. Common Stock.
• This ownership represents approximately 8.0% of the outstanding Common Stock of Sage Therapeutics, Inc.
• The percentage is based on 61,480,947 Common Stock outstanding as of February 4, 2025, as disclosed in Sage Therapeutics' Annual Report on Form 10-K.
• The filing indicates that the shares are held for investment purposes and not with the intent to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. The acquisition of a significant stake by an institutional investor can be seen as a neutral to slightly positive signal.

Positives

• The disclosure of a significant 8% stake by a group of institutional investors may be viewed by the market as a vote of confidence in Sage Therapeutics, Inc.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction, as it is a disclosure of beneficial ownership.

Industry Context

This filing represents a standard disclosure of a significant passive investment by an institutional group in a publicly traded company. It does not provide specific insights into broader industry trends but indicates continued institutional interest in the biotechnology and pharmaceutical sector, where Sage Therapeutics operates.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor group holding an 8% stake could be perceived positively, potentially signaling confidence in the company's value or future prospects.

Key Dates

Keywords

Sage Therapeutics, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Madison Avenue, Passive Investment, Equity Stake